The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND:Patients with peripheral T‐cell lymphomas (PTCLs) have inferior progression‐free survival (PFS) and overall survival (OS) compared with patients who have aggressive B‐cell non‐Hodgkin lymphoma. Because PTCLs over express multidrug resistance gene 1/P‐glycoprotein (MDR‐1/P‐gp), we devised platinum, etoposide, gemcitabine, and methylprednisolone (PEGS) with agents that are not substrates...
BACKGROUND:Randomized trials demonstrating the benefits of chemotherapy in patients with American Joint Committee on Cancer stage III colon cancer underrepresent persons aged ≥ 75 years. The generalizability of these studies to a growing elderly population remains unknown.
METHODS:Using the California Cancer Registry for 1994 through 2008, the authors conducted a population‐based study of postcolectomy...
BACKGROUND:In patients with high‐risk neuroblastoma, the reduction in primary tumor volume was measured during the early phase of induction chemotherapy as an indicator of early tumor response, and the authors investigated whether the degree of tumor volume reduction could predict outcome in these patients.
METHODS:Primary tumor volumes were measured both at diagnosis and at the first tumor response...
BACKGROUND:Neoadjuvant chemotherapy improves the survival of patients with high‐risk urothelial cancer. However, the lack of curative alternatives to cisplatin‐based chemotherapy is limiting for patients with neuropathy or hearing loss. Sequential chemotherapy also has not been well studied in the neoadjuvant setting. The authors explored sequential neoadjuvant ifosfamide‐based chemotherapy in a patient...
BACKGROUND:The American Society of Clinical Oncology Quality Oncology Practice Initiative endorses in their core measures that providers should discuss the goals of care (GOC) at the time of chemotherapy consent. GOC refers to chemotherapy treatment intent: cure versus noncure. In this study, the authors sought to determine whether attributes of patients and initial patient‐physician encounters were...
BACKGROUND:Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM).
METHODS:A phase 2 trial was conducted in chemotherapy‐naive patients with unresectable stage IV MM who were randomized to temozolomide (200 mg/m2 on days 1 through 5) and bevacizumab (10 mg/kg intravenously...
BACKGROUND.Life expectancy is increasing, and more patients are presenting with cancer at an advanced age (≥80 years). Optimal management for this group of patients has not been well defined.
METHODS.The South Australian Clinical Registry for Metastatic Colorectal Cancer (mCRC) collects data on all patients diagnosed since February 2006 in South Australia. The authors examined cancer characteristics,...
BACKGROUND: The objective of this study was to confirm the relation between plasma Epstein‐Barr virus (EBV) DNA (pEBV DNA) load and treatment outcomes after long‐term follow‐up in patients with nasopharyngeal carcinoma (NPC).
METHODS: In total, 210 patients with NPC were enrolled, including 99 previously reported patients and 111 new patients. They prospectively received treatment with induction chemotherapy...
BACKGROUND:Patients with early‐stage, nonbulky classic Hodgkin lymphoma (cHL) undergo intensive posttreatment radiologic surveillance despite having a low risk of disease recurrence. The current study attempted to evaluate the risk of disease recurrence and the value of radiologic surveillance in patients treated with the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone...
BACKGROUND:The time interval between surgery and initiation of adjuvant chemotherapy (ACT) may impact survival in colorectal and breast cancers. This is the first report describing the association between time to adjuvant chemotherapy (TTAC) and survival in non–small cell lung cancer (NSCLC).
METHODS:All cases of NSCLC diagnosed in Ontario, Canada, from 2004 to 2006 who underwent surgical resection...
BACKGROUND:The optimal management of bilateral Wilms tumor (BWT) is challenging, and their survival is lower than for unilateral tumors. This report discusses a large series of BWTs treated in Italy in the last 2 decades.
METHODS:This analysis concerns patients with synchronous BWT registered at Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) centers between 1990 and 2011; details on...
BACKGROUND:Between 30% and 50% of women who have high‐grade uterine leiomyosarcoma (uLMS) limited to the uterus at diagnosis remain progression‐free at 2 years. Adjuvant pelvic radiation does not improve outcome. The objective of the current study was to determine the 2‐year and 3‐year progression‐free survival (PFS) among a prospective cohort of women who received adjuvant gemcitabine plus docetaxel...
BACKGROUNDControversy exists regarding adjuvant oxaliplatin treatment among older patients with stage II and III colorectal cancer (CRC). This study sought to identify patient/tumor, physician, hospital, and geographic factors associated with oxaliplatin use among older patients.
METHODSIndividuals diagnosed at age > 65 with stage II or III CRC from 2004 through 2007 undergoing surgical resection...
The randomized first‐line trials, including the CRYSTAL trial, the OPUS trial, and the PRIME trial, have demonstrated the significant efficacy of cetuximab or panitumumab in patients with v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild‐type tumors. The addition of an antiepidermal growth factor receptor (anti‐EGFR)‐directed monoclonal antibody to chemotherapy for these patients significantly...
BACKGROUNDDepression is common during and after breast cancer treatment. However, the role of specific therapeutic modalities and related biologic mechanisms remains unclear. Radiation is an essential component of breast‐conserving therapy and may contribute to depression in patients with breast cancer through the activation of inflammatory pathways.
METHODSDepressive symptoms and inflammatory mediators,...
BACKGROUNDA previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S‐1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first‐line treatment for advanced non–small cell lung cancer (NSCLC). In the current study, the authors evaluated the efficacy and safety of combined S‐1, carboplatin, and bevacizumab followed by...
BACKGROUNDOptimal management of children with centrally located low‐grade glioma (LGG) is unclear. Initial interventions in most children are chemotherapy in younger and radiation therapy (RT) in older children. A better understanding of the inherent risk factors along with the effects of interventions on long‐term outcome can lead to reassessment of the current approaches to minimize long‐term morbidity...
BACKGROUNDChemotherapy has improved the outcome of patients with newly diagnosed osteosarcoma, but its role in relapsed disease is unclear.
METHODSWe reviewed the records of all patients who were treated for relapsed high‐grade osteosarcoma at our institution between 1970 and 2004. Postrelapse event‐free survival (PREFS) and postrelapse survival (PRS) were estimated, and outcome comparisons were...
BACKGROUNDChemotherapy‐induced neutropenia has been associated with prolonged survival selectively in patients on a conventional schedule (combined 5‐fluorouracil, leucovorin, and oxaliplatin [FOLFOX2]) but not on a chronomodulated schedule of the same drugs administered at specific circadian times (chronoFLO4). The authors hypothesized that the early occurrence of chemotherapy‐induced symptoms correlated...
BACKGROUNDUse of progression‐free survival (PFS) as a clinical trial endpoint in first‐line treatment of patients with metastatic urothelial carcinoma (UC) is attractive, but would be enhanced by establishing a correlation between PFS and overall survival (OS).
METHODSData was pooled from 7 phase 2 and 3 trials evaluating cisplatin‐based chemotherapy in metastatic UC. An independent cohort of patients...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.